FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal

May 1, 2026 11:07 AM EDT News Briefing FDA ap­proves Au­veli­ty for Alzheimer's ag­i­ta­tion; Es­pe­ri­on goes pri­vate in $1.1B deal ENDPOINTS 🟢 FDA ap­proves Ax­some Ther­a­peu­tics’ Au­veli­ty for Alzheimer’s ag­i­ta­tion: Ax­some said up to 76% of pa­tients with Alzheimer’s dis­ease have ag­i­ta­tion … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER